EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Open Access

Virological and Immunological Responses to Raltegravir and Dolutegravir in the Gut-Associated Lymphoid Tissue of HIV-Infected Men and Women

Michael D Weber, Elizabeth Andrews, Heather A Prince, Craig Sykes, Elias P Rosen, Camden Bay, Nicholas J Shaheen, Ryan D Madanick, Evan S Dellon, Kristina De Paris, Julie Ae Nelson, Cynthia L Gay und 1 weitere

Antiviral Therapy · 2018-08 · 23 (6) · 495-504

DOI: 10.3851/imp3236 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Antiviral Therapy, online erschienen am 01.08.2017. Verfasst von Michael D Weber und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Raltegravir (RTG) and dolutegravir (DTG) have different pharmacokinetic patterns in the gastrointestinal tract. To determine if this results in pharmacodynamic differences, we compared HIV RNA, HIV DNA and immunological markers in gut-associated lymphoid tissue (GALT) of HIV-infected participants receiving RTG or DTG with tenofovir+emtricitabine (TDF/FTC).

Methods

GALT specimens from the terminal ileum, splenic flexure and rectum were obtained by colonoscopy at a single time point in 20 adults treated with RTG ( n=10) or DTG ( n=10) with HIV RNA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdultAnti-HIV AgentsCD4 Lymphocyte CountCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesColon, TransverseDNA, ViralEmtricitabineFemaleGene ExpressionHIV InfectionsHIV-1Heterocyclic Compounds, 3-RingHumansIleumImmunity, InnateLymphoid TissueMaleMiddle AgedOxazines

Substanzen

Anti-HIV AgentsDNA, ViralEmtricitabineHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesRNA, ViralRaltegravir PotassiumReceptors, Antigen, T-Cell, gamma-delta

Autor:innen und Institutionen

  • University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA.
  • Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
  • Department of Biostatistics, University of North Carolina, Chapel Hill, NC, USA.
  • Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA.

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Weber, M. D., Andrews, E., Prince, H. A., Sykes, C., Rosen, E. P., Bay, C., Shaheen, N. J., Madanick, R. D., Dellon, E. S., De Paris, K., Nelson, J. A., Gay, C. L., & Kashuba, A. D. (2018). Virological and Immunological Responses to Raltegravir and Dolutegravir in the Gut-Associated Lymphoid Tissue of HIV-Infected Men and Women. Antiviral Therapy, 23(6), 495-504. https://doi.org/10.3851/imp3236

Vancouver

Weber MD, Andrews E, Prince HA, Sykes C, Rosen EP, Bay C, et al. Virological and Immunological Responses to Raltegravir and Dolutegravir in the Gut-Associated Lymphoid Tissue of HIV-Infected Men and Women. Antiviral Therapy. 2018;23(6):495-504. doi:10.3851/imp3236

BibTeX
@article{Weber2018,
  author = {Weber, Michael D and Andrews, Elizabeth and Prince, Heather A and Sykes, Craig and Rosen, Elias P and Bay, Camden and Shaheen, Nicholas J and Madanick, Ryan D and Dellon, Evan S and De Paris, Kristina and Nelson, Julie Ae and Gay, Cynthia L and Kashuba, Angela Dm},
  title = {Virological and Immunological Responses to Raltegravir and Dolutegravir in the Gut-Associated Lymphoid Tissue of HIV-Infected Men and Women},
  journal = {Antiviral Therapy},
  year = {2018},
  volume = {23},
  number = {6},
  pages = {495--504},
  doi = {10.3851/imp3236}
}
Kostenlos starten →